Lund, Sweden, 2012-08-17 09:29 CEST (GLOBE NEWSWIRE) --
Automatic Bone Scan Index (BSI) reflects chemotherapy response in patients with castration-resistant prostate cancer, according to a new clinical trial.
The first published clinical trial, showing that an automatic BSI calculated by the CAD system EXINI Bone ™ ( Bonenavi ™ in Japan) is effective in the evaluation of chemotherapy response in patients with bone metastatic prostate cancer, was recently published in British Journal of Urology International [ 1]. The conclusion of the study is: "The BSI Reflected the chemotherapy response in bone metastasis. The index detected small changes of bone metastasis response as Quantified values and was a strong prognostic indicator for patients with castration-resistant prostate cancer."
“Today there is a major focus on the treatment of patients with advanced prostate cancer with bone metastasis. Many new drugs are under development, or have recently been launched. It is very important to find an objective, reproducible and fast way to measure the results, both during the development and during the treatment, and this of course also applies to radiation therapy. This study shows that our unique product EXINI Bone ™, which automatically calculates the BSI, has an exciting and strong potential,” says Magnus Aurell, CEO EXINI Diagnostics AB.
Reference:
Prediction of survival benefit using an automated bone scan index in patient with castration-resistant prostate cancer. Mitsui et al, Department of Urology and Radiology, University School of Medicine, Izumo, Japan.
BJU Int. 21012 Jul 12.
Read more: http://www.ncbi.nlm.nih.gov/pubmed/22788759
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
